The Emerging Role of Altered D-Aspartate Metabolism in Schizophrenia: New Insights From Preclinical Models and Human Studies by Errico, Francesco et al.
REVIEW
published: 06 November 2018
doi: 10.3389/fpsyt.2018.00559
Frontiers in Psychiatry | www.frontiersin.org 1 November 2018 | Volume 9 | Article 559
Edited by:
Hsien-Yuan Lane,
China Medical University, Taiwan
Reviewed by:
Chih-Min Liu,
National Taiwan University Hospital,
Taiwan
Marek Schwendt,
University of Florida, United States
Maarten Van Den Buuse,
La Trobe University, Australia
*Correspondence:
Francesco Errico
francesco.errico@unina.it
Alessandro Usiello
usiello@ceinge.unina.it
Specialty section:
This article was submitted to
Molecular Psychiatry,
a section of the journal
Frontiers in Psychiatry
Received: 20 July 2018
Accepted: 17 October 2018
Published: 06 November 2018
Citation:
Errico F, Nuzzo T, Carella M,
Bertolino A and Usiello A (2018) The
Emerging Role of Altered D-Aspartate
Metabolism in Schizophrenia: New
Insights From Preclinical Models and
Human Studies.
Front. Psychiatry 9:559.
doi: 10.3389/fpsyt.2018.00559
The Emerging Role of Altered
D-Aspartate Metabolism in
Schizophrenia: New Insights From
Preclinical Models and Human
Studies
Francesco Errico 1*, Tommaso Nuzzo2, Massimo Carella 2, Alessandro Bertolino 3 and
Alessandro Usiello 4,5*
1 Department of Agricultural Sciences, University of Naples “Federico II”, Portici, Italy, 2 Translational Neuroscience Unit,
IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy, 3 Group of Psychiatric Neuroscience, Department of
Basic Medical Science, Neuroscience and Sense Organs, Aldo Moro University, Bari, Italy, 4 Laboratory of Behavioural
Neuroscience, Ceinge Biotecnologie Avanzate, Naples, Italy, 5 Department of Environmental, Biological and Pharmaceutical
Sciences and Technologies, Università Degli Studi Della Campania “Luigi Vanvitelli”, Caserta, Italy
Besides D-serine, another D-amino acid with endogenous occurrence in the mammalian
brain, D-aspartate, has been recently shown to influence NMDA receptor (NMDAR)-
mediated transmission. D-aspartate is present in the brain at extracellular level
in nanomolar concentrations, binds to the agonist site of NMDARs and activates
this subclass of glutamate receptors. Along with its direct effect on NMDARs,
D-aspartate can also evoke considerable L-glutamate release in specific brain areas
through the presynaptic activation of NMDA, AMPA/kainate and mGlu5 receptors.
D-aspartate is enriched in the embryonic brain of rodents and humans and its
concentration strongly decreases after birth, due to the post-natal expression of the
catabolising enzyme D-aspartate oxidase (DDO). Based on the hypothesis of NMDAR
hypofunction in schizophrenia pathogenesis, recent preclinical and clinical studies
suggested a relationship between perturbation of D-aspartate metabolism and this
psychiatric disorder. Consistently, neurophysiological and behavioral characterization
of Ddo knockout (Ddo−/−) and D-aspartate-treated mice highlighted that abnormally
higher endogenous D-aspartate levels significantly increase NMDAR-mediated synaptic
plasticity, neuronal spine density and memory. Remarkably, increased D-aspartate
levels influence schizophrenia-like phenotypes in rodents, as indicated by improved
fronto-hippocampal connectivity, attenuated prepulse inhibition deficits and reduced
activation of neuronal circuitry induced by phencyclidine exposure. In healthy humans,
a genetic polymorphism associated with reduced prefrontal DDO gene expression
predicts changes in prefrontal phenotypes including greater gray matter volume
and enhanced functional activity during working memory. Moreover, neurochemical
detections in post-mortem brain of schizophrenia-affected patients have shown
significantly reduced D-aspartate content in prefrontal regions, associated with
increased DDO mRNA expression or DDO enzymatic activity. Overall, these findings
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suggest a possible involvement of dysregulated embryonic D-aspartate metabolism in
schizophrenia pathophysiology and, in turn, highlight the potential use of free D-aspartate
supplementation as a new add-on therapy for treating the cognitive symptoms of this
mental illness.
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INTRODUCTION
Although L-amino acids aremostly used for protein synthesis and
metabolic processes in eukaryotes, some free amino acids are
present in a substantial amount in D configuration inmammalian
tissues, including humans. In particular, free D-aspartate (D-
Asp), and D-serine (D-Ser) are enriched in the brain where
they emerge in an age- and region-dependent manner (1–5).
Since its discovery at the beginning of the 90s (6), D-Ser has
been extensively studied in the mammalian brain. Nowadays,
it is well known that D-Ser is an endogenous N-Methyl D-
Aspartate (NMDA) receptor (NMDAR) co-agonist that regulates
the activation of glutamatergic excitatory synapses (7–10), thus
influencing diﬀerent NMDAR-dependent functions, such as
brain development (11), synaptic transmission and plasticity
(12–17), and behaviors (18–20). In this line, alteration of D-Ser
metabolism has been linked to pathological conditions associated
with NMDAR dysfunction, including schizophrenia (21–23).
Unlike D-Ser, the neurobiological role of D-Asp has been most
significantly studied only from the last decade, so it is still
poorly defined. Nonetheless, we know today that D-Asp is able to
directly modulate NMDAR-mediated transmission and functions
in rodents, and dysregulation of its metabolism occurs in the
brain of schizophrenia patients. In this review, we will summarize
the evidence collected in both animal models and humans that
have led to hypothesize a role for this atypical amino acid in
schizophrenia pathophysiology.
PRESENCE OF FREE D-ASPARTATE AND
ITS METABOLIC REGULATION IN THE
MAMMALIAN BRAIN
The presence of free D-Asp in the mammalian brain was reported
for the first time by Dunlop et al. in the mid-80s (1). This
pioneering observation has been followed by many other studies
in rodents and humans that overall showed a transient emergence
of D-Asp in the brain, characterized by a peak of concentration
during developmental stages and a drastic fall after birth (1–
4, 24, 25). Among these studies, HPLC detections obtained by
Hashimoto et al. revealed that the amount of D-Asp in the human
prefrontal cortex (PFC) homogenates even exceeds that of the
corresponding L-form at gestational week 14 (3). Consistent
with this finding, in the rat brain D-Asp appears at embryonic
day 12 (E12) selectively in non-proliferating neuroblasts but
not in mitotic cells of the ventrocaudal forebrain, midbrain,
and hindbrain (24). In the ventral side of the forebrain, D-
Asp emerges in cell bodies of migrating neuroblasts and then
shifts to axons once these cells have reached the outer layer of
neural epithelium. Between E14 and E20, D-Asp concentration
increases and spreads to the whole brain. In particular, in the
cerebral cortex, D-Asp is present in both the cell bodies and
projections of neuroblasts (24). In another work, Snyder et al.
revealed that D-Asp is present in a substantial amount at birth
in the forebrain regions, like the cortex and part of the midbrain
(25). At post-natal day 2, D-Asp extends to the hindbrain and
cerebellum and is enriched in the subventricular zone and the
cortical plate of the cerebral cortex, the CA1-CA3 area and the
dentate gyrus of the hippocampus, and the external granular layer
of the cerebellum. In this last brain region, D-Asp staining is
associated with granule cells that have not yet migrated to their
definitive location (25). One week after birth, D-Asp decreases
and almost disappears in one-month-old brains (26). Notably, in
both prenatal and postnatal phases, D-Asp seems to be present
exclusively in neurons but not in glial cells (25, 26).
The peculiar spatiotemporal occurrence of D-Asp in the
embryonic brain suggests that this atypical molecule is mainly
produced through a de novo biosynthetic mechanism (Figure 1).
Accordingly, a time-dependent accumulation of D-Asp was
demonstrated in PC12 cells cultured in D-Asp-free medium
(27, 28). Further evidence resulted from primary cultures of rat
embryonic neurons in which [14C]-D-Asp was produced starting
from [14C]-L-Asp precursor (25). A pyridoxal 5’-phosphate
(PLP)-dependent glutamate-oxalacetate transaminase 1-like 1
(Got1l1) was identified as the enzyme that converts L-Asp to
D-Asp in the adult mouse brain (29). However, subsequent
findings have demonstrated that knockout of Got1l1 gene does
not produce any change in cerebral D-Asp levels of mutant mice
(30). Interestingly, two studies have shown that serine racemase
(SR), the only known enzyme responsible for D-Ser biosynthesis
in the mammalian brain (31), could be involved also in D-Asp
production, at least in some brain areas (32, 33). Indeed, Sr
knockoutmice display considerably decreased D-Asp levels in the
forebrain regions (around 50–60 %) but not in the cerebellum
(32, 33). Remarkably, overexpression of SR in rat PC12 cells
resulted in intracellular D-Asp increase while genetic ablation
of Sr in these cells did not produce changes in this D-amino
acid levels (33), further supporting that besides SR an additional
enzymatic activity for D-Asp biosynthesis is present in mammals.
While D-Asp biosynthetic pathway is still unclear, the enzyme
responsible for D-Asp degradation, D-aspartate oxidase (DDO,
or DAPOX EC 1.4.3.1), has been well known for a long time (34).
DDO is a peroxisomal flavoenzyme (35, 36) that oxidizes D-Asp
in presence of H2O and O2, producing α-oxaloacetate, H2O2,
and NH+4 (Figure 1) (37–39). DDO is inactive toward D-Ser (40)
that is degraded by its homologous flavoenzyme, D-amino acid
Frontiers in Psychiatry | www.frontiersin.org 2 November 2018 | Volume 9 | Article 559
Errico et al. Dysregulated D-Aspartate Metabolism in Schizophrenia
FIGURE 1 | Schematic pathway of the biochemical transformations of D-aspartate in the mammalian brain. D-aspartate is likely generated through stereochemical
inversion of L-aspartate. Recent studies in mice have shown that Serine racemase is partially involved in D-aspartate biosynthesis although it is still unclear whether its
activity toward aspartate is region- and/or age-dependent. These studies also suggested that there should be a main racemase activity specifically involved in
D-aspartate generation. On the other hand, it is acknowledged that D-aspartate is degraded by the enzyme D-aspartate oxidase through a process of deaminative
oxidation (requiring flavin adenine dinucleotide, FAD, as a prosthetic group) that produces the ketoacid α-oxalacetate, hydrogen peroxide, and ammonia. In addition,
D-aspartate can be converted into its N-methyl derivative, NMDA, possibly through a D-aspartate methyltransferase activity that uses s-adenosylmethionine (SAM) as
a methyl donor. See the main text for further descriptions.
oxidase (DAAO, EC 1.4.3.3) (41–43). A specific tripeptide signal
at the C-terminus of DDO targets this enzyme to peroxisomes
(40, 44), where the toxic H2O2 produced by D-Asp oxidation
can be safely removed by peroxisome-resident catalases
(45).
Consistent with a primary role for DDO activity in controlling
its substrate concentration, it has been reported that spatial
and temporal expression of this enzyme is reciprocal to D-
Asp (26, 35, 46). During mouse lifespan, the postnatal decrease
of cerebral D-Asp is mirrored by a time-dependent increase
of Ddo gene expression, as Ddo mRNA levels are very low
from E14 to 1 week of age and then strongly rise during
the following weeks until adult phase (46). Interestingly,
the postnatal increase of Ddo transcript levels is temporally
associated with concomitant dramatic demethylation of the
putative promoter region of Ddo gene. In agreement with an
influence of DNA methylation on Ddo mRNA expression, it
has been shown that treatment with the DNA demethylating
agent, azacitidine, triggers the expression of Ddo transcript
in embryonic cortical neurons, which do not express Ddo
gene in physiological conditions (46). Notably, the temporal
pattern of Ddo mRNA expression reported in the mouse brain
matches closely with the substantial increase in DDO enzymatic
activity found in the rat brain during the first weeks of
life (35). Like D-Asp, also DDO is prominently localized in
neurons, and only marginally expressed in glial population (36).
Overall, reciprocal spatiotemporal localization of DDO and D-
Asp suggests that during adulthood this enzyme is necessary
to remove its endogenous substrate from brain regions where
D-Asp is no more required and, indeed, could be functionally
detrimental and neurotoxic for neuronal activity and survival,
as found in the brain of elderly constitutive knockout mice
for Ddo gene (Ddo−/−) (46–48). The substantial and persistent
accumulation of D-Asp in the brain of Ddo−/− mice further
suggests that DDO is the only enzyme that catalyzes the
endogenous degradation of D-Asp, throughout the entire animal
lifespan (47, 49, 50).
PHARMACOLOGICAL FEATURES OF
D-ASPARTATE
Pioneering neuropharmacological studies performed in the
second half of the 80s, aimed at finding molecules with agonistic
or antagonistic activity for L-glutamate (L-Glu) receptors,
highlighted that D-Asp is able to bind to the L-Glu site of
NMDARs (51–55). In particular, one of these works revealed that
the eﬃciency of D-Asp in displacing the NMDAR antagonist,
D-AP5, in rat brain membranes is the same as NMDA and
around 10 times lower than L-Glu (54). Many years later, a series
of electrophysiological observations demonstrated that D-Asp
not only binds to NMDARs but also activates these receptors.
Indeed, local application of D-Asp on adult mouse brain slices
triggers inward currents in both hippocampal CA1 pyramidal
neurons and striatal GABAergic medium spiny neurons, which
are strongly reduced by the competitive and non-competitive
NMDAR antagonists, D-AP5 and MK-801, respectively (56,
57). D-Asp activates NMDARs through the binding to each of
the GluN2 subunits (58), and induces the transient increase
of intracellular Ca2+ (47). Notably, a small but significant
percentage of the currents triggered by D-Asp application still
endure even after application of high doses of MK-801 (47,
56, 58). The persistence of D-Asp-mediated currents under
conditions of NMDAR blockade suggests that this D-amino
acid may be able to aﬀect, at least in part, additional receptor
complexes. Accordingly, D-Asp can also stimulate metabotropic
mGlu5 receptors in mouse and rat brain (59–61).
The endogenous occurrence of D-Asp in the brain and
its main ability to activate NMDARs are consistent with an
involvement of this D-amino acid in the in vivo modulation
of glutamatergic synaptic functioning. In agreement with this
idea, early studies have suggested that D-Asp can transit
through the extracellular space by transporter mechanisms
enabling its release and reuptake. Accordingly, experiments
using diﬀerent ex vivo preparations (tissue slices, cells or
synaptosomes) demonstrated that D-Asp is released through
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exocytotic processes mediated by vesicular Ca2+ (25, 62–65). D-
Asp is contained in membrane-bound organelles, identified as
secretory granules (in PC12 cells) (64) or synaptic vesicles (in
synaptosome preparation) (66), in which this D-amino acid is
actively stored through still unknown transporter systems. In
line with in vitro data, Usiello et al. confirmed the existence
of Ca2+-dependent D-Asp release in the cortex of living mice.
Indeed, in microdialysis studies performed in the PFC of freely
moving animals they showed that D-Asp is present in the
extracellular space at nanomolar concentration (46, 61) and when
dialysates were collected in Ca2+-free artificial cerebrospinal
fluid, extracellular concentration of D-Asp dropped below the
limit of HPLC detection. Extracellular D-Asp has been also
recently demonstrated in the brain of domestic chicks, where it
decreases in an age-dependent manner and is transiently induced
following high K+ stimuli (67). The recent evidence that D-Asp
occurs also in the extracellular space confirms the idea that this D-
amino acid has the potential to bind to NMDARs also in vivo and,
in turn, to aﬀect the glutamatergic neurotransmission dependent
on this receptor subclass. In addition to Ca2+-dependent eﬄux
system, further studies reported that D-Asp may also be released
through spontaneous processes (25, 68, 69) or mechanisms
involving L-Glu exchange (70, 71).
Diﬀerent studies suggest that intracellular uptake of D-Asp
may depend by L-Glu/L-Asp transporter system, which moves
excitatory amino acids against their concentration gradient using
the Na+/K+ electrochemical gradient. Interestingly, while on
one side this carrier system recognizes only the L-enantiomer
of Glu, on the other it is able to take up both Asp enantiomers
with approximately the same eﬃciency (72). In line with an
involvement of L-Glu/L-Asp transporters in the reuptake of D-
Asp, autoradiographic and immunostaining experiments have
shown that D-Asp preloading on rodent hippocampal and
cerebellar slices causes a strong labeling in glutamatergic axons
and in surrounding glial processes (73–75). No direct evidence is
so far available about the existence of selective D-Asp reuptake
mechanisms in the in vivo brain. Nonetheless, the drastic and
fast reduction of cortical extracellular D-Asp after experimental
removal of Ca2+ from the artificial cerebrospinal fluid reported
in microdialysis studies (46, 61), seems to suggest the presence
of an active and eﬃcient mechanism of D-Asp clearance in the
mammalian brain.
PRECLINICAL MODELS WITH A
NON-PHYSIOLOGICAL INCREASE OF
D-ASPARTATE CONTENT IN THE BRAIN
The generation of Ddo knockout mice (Ddo−/−) in two
independent laboratories (49, 50) has been a turning point for the
comprehension of the in vivo role of D-Asp and its catabolizing
enzyme. BothDdo−/− mouse lines display higher D-Asp levels in
the brain and peripheral organs, but comparable L-Asp (49, 50)
and L-Glu content (50), compared to their respective controls. In
more detail, HPLC detection in homogenates deriving from the
hippocampus, striatum, cortex, cerebellum and olfactory bulbs
showed ∼10- to 20-fold increase in D-Asp levels in Ddo−/−
mice, compared to wild-type animals (46, 47, 56, 57). Along
with D-Asp, also the levels of the N-methyl derivative of D-
Asp, NMDA, were increased in Ddo−/− brain homogenates (47,
49). In this regard, biochemical findings indicated that cerebral
NMDA could be generated through the transfer of a methyl
group from S-adenosyl methionine to D-aspartate catalyzed by a
methyltransferase activity (Figure 1) (76). In line with the rise of
total D-Asp levels in brain homogenates, recent evidence on PFC
dialysates has indicated that Ddo−/− mice display significantly
increased D-Asp concentration also in the extracellular fraction,
compared to Ddo+/+ littermates (a rise of about five times,
∼100 nM in Ddo−/− vs.∼20 nM in Ddo+/+) (46).
Besides Ddo gene targeting, another experimental approach
has been widely used in the last years to raise the cerebral levels
of D-Asp. This approach consists of the oral administration of D-
Asp to animals for periods of one-two months until the age of
two-three months. In relation to the brain region analyzed, such
a treatment produces an approximately 2- to 5-fold increase in D-
Asp content in homogenate samples, compared to the same areas
of untreated mice (56–58, 61). Such rise is substantially lesser
than that produced byDdo gene targeting since the DDO enzyme
expressed in the brain of adult D-Asp-treated mice is able to limit
the further increase of this D-amino acid levels. In line with the
eﬀect of Ddo gene ablation, also the exogenous administration
of D-Asp is able to induce a significant extracellular increase
of this molecule in the PFC of freely moving mice, in both
chronic and acute conditions (61). In particular, chronic oral
administration of D-Asp for 1 month produces an increase in the
same order of magnitude as Ddo knockout (∼80 nM in treated
mice vs. ∼20 nM in untreated mice). On the other hand, acute
D-Asp injection (at the dose of 500 mg/kg) is able to trigger
a transient and rapid elevation of D-Asp levels already 20min
post-administration (from∼20 to∼500 nM). Consistent with the
observations of Usiello et al. (61), a very recent study showed that
intragastric infusion of D-Asp to rats reaches the hippocampus in
15min via blood circulation (77). Taken together, these findings
have a potential translational relevance as they highlight the
ability of D-Asp to cross the blood-brain barrier, as described
so far only for the D-stereoisomers of Ser and proline (78, 79).
Strikingly, both chronic oral administration and acute injection
of D-Asp are able to evoke a significant prefrontal eﬄux of
L-Glu (48, 61) through the presynaptic activation of NMDA,
mGlu5, and AMPA/kainate receptors triggered by this D-amino
acid (61). Overall, these data indicate that D-Asp could influence
glutamatergic neurotransmission not only through its direct
binding to the L-Glu site of postsynaptic NMDARs but also
through its ability to evoke the presynaptic release of endogenous
L-Glu in selective brain regions.
D-ASPARTATE AFFECTS FUNCTIONAL
AND STRUCTURAL NEURONAL
PROPERTIES DEPENDENT ON NMDA
RECEPTORS ACTIVATION
The results described so far suggest that D-Asp stimulates also
in vivo the glutamatergic transmission in adult rodents. In this
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regard, electrophysiological evidence obtained in the last 10
years has revealed that higher D-Asp content enhances NMDAR-
dependent early-phase and late-phase long-term potentiation
(E-LTP and L-LTP, respectively) in the CA1 area of the
hippocampus of both adult Ddo−/− and chronically D-Asp-
treated mice (47, 56, 58, 80). Interestingly, the induction of
E-LTP protocol, which causes a decaying LTP in Ddo+/+ and
untreated mice, is suﬃcient to maintain an enduring L-LTP
(lasting for more than 160min following tetanic stimulation)
in Ddo−/− and D-Asp-treated mice (80). In both models, D-
Asp-dependent L-LTP is insensitive to rapamycin administration
but is suppressed by cytochalasin D (80), a potent inhibitor
of actin polymerization. Moreover, chronic treatment with D-
Asp increases the frequency of NMDAR-mediated miniature
excitatory post-synaptic currents in pyramidal neurons of the
medial PFC layer II/III (80). Remarkably, in line with the
enhanced glutamatergic transmission, mice chronically treated
with D-Asp display stronger metabolic activity in fronto-
hippocampal areas, measured by basal cerebral blood volume-
weighted functional magnetic resonance imaging (fMRI) (80). In
this regard, increased synchronization between the hippocampus
and cortical regions has been also recently produced through
D-Asp gavage in awake rats subjected to blood oxygen level
dependent (BOLD) fMRI (77). Changes in synaptic functioning
are commonly associated with structural synaptic variations in
dendritic morphology (81, 82). This relationship is observed
also in the brain of Ddo−/− and D-Asp-treated mice, in
which facilitated induction of late-phase synaptic plasticity
is mirrored by increased dendritic length and spine density,
and greater dendritic arborisation in pyramidal neurons of
the PFC and hippocampus (80). These in vivo results are
inferred also from very recent in vitro findings showing that
the exogenous application of D-Asp to rat hippocampal slices
produces a rapid genesis of middle size spines of CA1 neurons
via an actin-sensitive mechanism, as early as 2 h after treatment
(77). Consistent with structural and functional enhancement
in cortico-hippocampal synaptic plasticity, Ddo−/− and D-
Asp treated mice display significant improvements in the
cognitive domain of spatial memory when tested in the hidden-
platform version of the Morris water maze and contextual
fear conditioning (47, 57), two behavioral tasks involving the
hippocampal activation of NMDARs (83, 84). Similar behavioral
observations were reported also in D-Asp-treated rats (85).
However, if on the one hand NMDARs promote synaptic
strength and connectivity, on the other they can produce
neuronal death if their stimulation is abnormally intense or
temporarily too long (86). In line with detrimental NMDAR-
related eﬀects, persistent increase of D-Asp levels results in
precocious decay of basal glutamatergic transmission, synaptic
plasticity and hippocampal reference memory in 13/14-month-
old Ddo−/− (47), mirrored by loss of excitatory glutamatergic
synapses and reduction of synaptic GluN1 and GluN2B subunits
(87). In addition, a recent study also revealed that the lack
of DDO leads to severe neuroinflammation processes and cell
death in an age-dependent manner (46). In line with the results
obtained in elderly Ddo−/− animals, also aged C57BL/6J mice
treated with D-Asp (at the dose of 20mM) for 12 months display
similar deficits in hippocampal NMDAR-mediated synaptic
plasticity despite such prolonged administration results in only
two-fold D-Asp increase in this brain region (58). However, it
should be noted that the interruption of D-Asp treatment for 3
weeks is suﬃcient to fully rescue the NMDAR-dependent LTP
deficits and that such a long administration schedule does not
produce locomotor and anxiety-like alterations in aged animals
that, on the contrary, display a significant cognitive improvement
in cue-dependent fear conditioning paradigm (58). Overall, these
data point out that the “Yin and Yang” behavior of NMDARs (86)
can be recapitulated in diﬀerent stages of life by deficient DDO
activity in the mouse brain.
D-ASPARTATE AFFECTS
SCHIZOPHRENIA-RELATED FEATURES
AND ACTIVATION OF NEURONAL
CIRCUITS IN THE RODENT BRAIN
Accumulating evidence supports the hypothesis that a
developmental hypofunction of NMDARs is a causative
factor in the etiology and pathophysiology of schizophrenia (88–
91). In the wake of the glutamatergic model of schizophrenia,
several clinical, pharmacological, imaging, and genetic findings
suggest today that dysfunctional metabolism of the NMDAR
co-agonist, D-Ser, may produce NMDAR-mediated alterations
leading to the manifestation of this mental illness (21–23, 92).
In the last years, a number of preclinical observations
have shown that also D-Asp may contribute to influence
some NMDAR-dependent phenotypes related to schizophrenia.
For instance, behavioral studies performed in adult Ddo−/−
and D-Asp-treated mice have revealed that chronic D-Asp
elevation significantly reduces the prepulse inhibition (PPI)
deficit induced by psychotomimetic drugs like amphetamine
and MK-801 without aﬀecting basal properties of sensorimotor
filtering (57). In addition, Ddo−/− mice display a substantial
reduction of motor hyperactivity, ataxia and PPI disruption
triggered by acute administration of phencyclidine (PCP) (93,
94), the drug that better than any other models schizophrenia
symptoms in both humans and rodents (22, 95–97). In line with
behavioral observations, increased levels of D-Asp in Ddo−/−
mice are also able to counteract the dysfunctional cortico-limbo-
thalamic activation induced by PCP, as measured by fMRI
(94). Moreover, consistent with increased dendritic length and
spine density, resting-state fMRI has shown greater cortico-
hippocampal connectivity in the brain of Ddo−/− mice (94).
Increased functional connectivity between the hippocampus
and cortex has been recently found also in the rat brain
following intragastric administration of D-Asp (77). Since several
clinical and preclinical studies suggest the occurrence of cortico-
hippocampal dysconnectivity in schizophrenia (98, 99), the in
vivo imaging data obtained in animal models with higher D-Asp
levels highlight a potential translational relevance for D-Asp in
treating this mental illness. Consistently, increased levels of D-
Asp are also able to prevent corticostriatal long-term depression
(57), a synaptic feature reported also in mice chronically treated
with the typical antipsychotic haloperidol (100).
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REDUCED D-ASPARTATE
CONCENTRATION IN THE HUMAN
PREFRONTAL CORTEX OF
SCHIZOPHRENIA POST-MORTEM BRAIN
Based on the results obtained in preclinical research, recent
studies have focused the attention on humans in order to assess
D-Asp metabolism and its impact on phenotypes relevant to
schizophrenia. So far, two diﬀerent studies have measured D-
Asp levels in two diﬀerent cohorts of post-mortem brain samples
deriving from patients with schizophrenia and corresponding
non-psychiatric controls (101, 102). The first study, performed
on a small number of samples (7–10 subjects/diagnosis), revealed
reduced D-Asp levels (about 40%) in the post-mortem PFC
of schizophrenia-aﬀected patients (101), linked to significantly
increased DDO mRNA levels in the same brain area (94).
However, neither methylation changes in the putative DDO
promoter nor gross aberrations in this gene, including insertion,
deletion, frameshift, or nonsense mutations were found in the
same samples (94). Also the second study, performed on a
larger number of samples (20 subjects/diagnosis/brain region),
reported a significant D-Asp reduction (about 30%) selectively
in the dorsolateral PFC (DLPFC) but not in the hippocampus
of patients, compared to the respective brain regions of non-
psychiatric subjects (102). Interestingly, the biochemical analysis
pointed out that reduced content of D-Asp in the DLPFC of
schizophrenia-aﬀected subjects is associated with an aberrant
increase in DDO enzymatic activity (102). However, diﬀerently
from the first cohort of samples (101), DDO gene expression,
as well as DNA methylation status, was comparable between
diagnoses (102, 103). Moreover, western blotting analysis of SR,
regarded as an enzyme involved in D-Asp biosynthesis (32, 33),
revealed no changes between schizophrenia-aﬀected patients and
healthy individuals (102).
Furthermore, to assess the eﬀect of putative alteration
of D-Asp metabolism in the human brain, another study
reported the association among DDO gene variations, prefrontal
DDO mRNA expression and structural/functional prefrontal
phenotypes relevant to schizophrenia (80). Within this study,
an in silico analysis performed on 268 post-mortem brains
of non-psychiatric subjects (deriving from BrainCloud bank,
http://braincloud.jhmi.edu) revealed that the C allele of the
single nucleotide polymorphism (SNP), rs3757351, mapping in
an intronic region of DDO gene, is associated with reduced
prefrontal expression ofDDO transcript, compared to the T allele
and, thus, may hypothetically predict increased endogenous D-
Asp levels in the PFC. This result led authors to perform in vivo
imaging analyses whose results disclosed that healthy individuals
bearing the C allele also display increased prefrontal gray matter
volume and greater prefrontal activity, compared to the subjects
with the T allele, when they were subjected to 1- and 2-Back
working memory tasks.
Besides the neurochemical and functional studies reported
above in post-mortem schizophrenia brain, a recent preclinical
research by Usiello et al. revealed that the modulation of D-
Asp metabolism could be instrumental for the mechanism of
action by which a common second-generation antipsychotic,
olanzapine, influences glutamatergic cortical neurotransmission
(61). In particular, they found that olanzapine, diﬀerently from
other typical and atypical antipsychotics, inhibits the enzymatic
activity of DDO in vitro. Moreover, in agreement to in vitro
results, chronic administration of this antipsychotic is able to
increase the extracellular levels of D-Asp and L-Glu in the PFC
of freely moving Ddo+/+ mice, but not in Ddo−/− animals (61).
CONCLUSIONS AND FUTURE
PERSPECTIVES
The findings described in the present review highlight that
increased levels of the endogenous NMDAR agonist, D-Asp,
impact on a series of functional, and structural phenotypes
relevant to schizophrenia. Despite the knowledge on the
neurobiological role of D-Asp and its potential involvement in
schizophrenia is significantly enhanced in the last years, many
issues remain still unsolved or deserve further clarification.
For instance, it seems clear today that D-Asp is synthesized
in the brain where it is subjected to release and reuptake
mechanisms that enable its neuromodulatory activity, but it is
still unclear what are the specific enzymes and transport systems
responsible for such processes. Is there a selective enzymatic
activity responsible for D-Asp production in the mammalian
brain? Moreover, the influence of SR upon the endogenous D-
aspartate level still waits to be clarified in the human brain. If SR
is actually involved in D-Asp biosynthesis in the human brain,
to what extent it contributes to the generation of this D-amino
acid and in which spatiotemporal window? Are there relevant
genetic SR variants associated to dysregulation of cerebral D-
Asp levels? These questions may help to elucidate the eﬀective
significance of altered D-Asp metabolism in schizophrenia since
SR is in the list of the largest genome-wide association study as
a susceptibility gene for schizophrenia (92). The assessment of
a D-Asp involvement in schizophrenia will necessarily undergo
the verification of altered D-Asp amount in further schizophrenia
brains. Indeed, the results of a dysregulated D-Asp metabolism
in post-mortem brain samples so far achieved are encouraging
but refer only to a limited number of samples, analyzed by the
same research team (101, 102). Therefore, this issue deserves
to be further assessed also by other laboratories and in a larger
number of post-mortem brain tissues as well as in other biological
materials such as the peripheral blood and cerebrospinal fluid of
patients (FE, AB and AU personal communication).
Another important aim that should be pursued in future
studies concerns the evaluation of the potential therapeutic
value of D-Asp in schizophrenia treatment. In support of its
translational application, D-Asp is nowadays approved for the
use in humans, and commercialized as a dietary supplement.
Accordingly, recent studies have shown that D-Asp treatment has
no toxicological consequences or influences on hormonal activity
of the hypothalamic-pituitary-gonadal axis and the mass of
skeletal muscle (104–108). Besides D-Asp administration, future
therapeutic strategies may be disclosed by the identification of
compounds with inhibitory activity against DDO and, thus, able
Frontiers in Psychiatry | www.frontiersin.org 6 November 2018 | Volume 9 | Article 559
Errico et al. Dysregulated D-Aspartate Metabolism in Schizophrenia
to indirectly enhance the availability of cerebral D-Asp. Novel
DDO inhibitors have been so far functionally assayed in vitro by
Homma et al. (109) and await further in vivo characterization to
test their clinical validity.
Finally, future research needs to provide clear evidence
of the potential role of embryonic D-Asp metabolism in the
pathophysiological mechanisms leading to schizophrenia.
In this regard, it is very important to underline that the
etiology of this psychiatric disorder is likely to involve
genetic and environmental risk factors emerging during
the neurodevelopmental stages (110–113), in coincidence
with the peak of D-Asp, and aﬀecting several processes
controlled by NMDARs, such as neurogenesis, survival,
migration and formation of brain circuits (114–116).
Therefore, we speculate that dysfunctional D-Asp metabolism
occurring during neurodevelopment may aﬀect early critical
processes dependent on NMDARs and, in turn, contribute
to schizophrenia vulnerability. The recent generation of
a genetic mouse model with prenatal reduction of D-Asp
levels (FE and AU personal communication) may aid
to disclose the importance of the transient occurrence
of D-Asp in developmental brain processes and, in
turn, the potential involvement of dysregulated D-Asp
metabolism in a neurodevelopmental psychiatric disorder
like schizophrenia.
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